Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 4 records in total 4
    records per page




    K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia HP

    Authors: Stanley Perlman; Jian Zheng; LOK YIN ROY WONG; Kun Li; Abhishek K Verma; Miguel E Ortiz Bezara; Christine Wohlford-Lenane; Mariah R. Leidinger; Michael C. Kundson; David K. Meyerholz; Paul B McCray Jr.

    doi:10.1101/2020.08.07.242073 Date: 2020-08-10 Source: bioRxiv

    The ongoing COVID-19 pandemic is associated with substantial morbidity and mortality. While much has been learned in the first months of the pandemic, many features of COVID-19 pathogenesis remain to be determined. For example, anosmia HP anosmia MESHD is a common presentation and many patients with this finding show no or only minor respiratory signs. Studies in animals experimentally infected with SARS-CoV-2, the cause of COVID-19, provide opportunities to study aspects of the disease not easily investigated in human patients. COVID-19 severity ranges from asymptomatic TRANS to lethal. Most experimental infections provide insights into mild disease. Here, using K18-hACE2 mice that we originally developed for SARS studies, we show that infection with SARS-CoV-2 causes severe disease in the lung, and in some mice, the brain. Evidence of thrombosis MESHD and vasculitis HP vasculitis MESHD was detected in mice with severe pneumonia HP pneumonia MESHD. Further, we show that infusion of convalescent plasma SERO (CP) from a recovered COVID-19 patient provided protection against lethal disease. Mice developed anosmia HP anosmia MESHD at early times after infection MESHD. Notably, while treatment with CP MESHD prevented significant clinical disease, it did not prevent anosmia HP anosmia MESHD. Thus K18-hACE2 mice provide a useful model for studying the pathological underpinnings of both mild and lethal COVID-19 and for assessing therapeutic interventions.

    Evaluation of Convalescent Plasma SERO versus Standard of Care for the Treatment of COVID-19 in Hospitalazed Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial

    Authors: Elena Diago-Sempere; Jose Luis Bueno; Aranzazu Sancho-Lopez; Elena Munez-Rubio; Ferran Torres; Rosa Malo de Molina; Ana Fernandez-Cruz; Isabel Salcedo De Diego; Ana Velasco-Iglesias; Concepcion Payares Herrera; Inmaculada Casas Flecha; Cristina Avendano-Sola; Rafael Duarte Palomino; Antonio Ramos-Martinez; Belen Ruiz-Antoran

    doi:10.1101/2020.07.31.20165720 Date: 2020-08-04 Source: medRxiv

    Background: COVID-19 is a respiratory disease MESHD caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but the severity of the condition prompted the use of several pharmacological and non-pharmacological interventions. It has long been hypothesized that the use of convalescent plasma SERO (CP) from infected MESHD patients who have developed an effective immune response is likely to be an option for the treatment of patients with a variety of severe acute respiratory infections MESHD ( SARI MESHD) of viral etiology. The aim of this study is to assess the efficacy and safety of convalescent plasma SERO in adult TRANS patients with severe COVID-19 pneumonia HP pneumonia MESHD. Methods/Design: The ConPlas-19 study is a multicenter, randomized, open-label controlled trial. The protocol has been prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. The study has been planned to include 278 adult TRANS patients hospitalized with severe COVID-19 infection not requiring mechanical ventilation (invasive or non-invasive). Subjects are randomly assigned in a 1:1 ratio (139 per treatment arm), stratified by center, to receive intravenously administered CP (single infusion) plus SOC or SOC alone, and are to be followed for 30 days. The primary endpoint of the study is the proportion of patients that progress to categories 5, 6 or 7 (on the 7-point ordinal scale proposed by the WHO) at day 15. Interim analyses for efficacy and/or futility will be conducted once 20%, 40%, and 60% of the planned sample size are enrolled and complete D15 assessment. Discussion: This clinical trial is designed to evaluate the efficacy and safety of passive immunotherapy with convalescent plasma SERO for the treatment of adult TRANS patients hospitalized with COVID-19. The results of this study are expected to contribute to establishing the potential place of CP MESHD in the therapeutics for a new viral disease. Trial registration: Trial registration at clinicaltrials.gov; Registration Number: NCT04345523; https://clinicaltrials.gov/ct2/show/NCT04345523; Registered on 30 March, 2020. First posted date: April 14, 2020. Keywords: COVID-19, randomized, controlled trial, protocol, convalescent plasma SERO (CP), antibodies SERO.

    Evaluation of Convalescent Plasma SERO Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial

    Authors: Elena Diago-Sempere; Aranzazu Sancho-López; Jose Luis Bueno; Elena Múñez-Rubio; Ferran Torres; Rosa Malo de Molina; Ana Fernández-Cruz; Isabel Salcedo de Diego; Ana Velasco-Iglesias; Concepción Payares-Herrera; Inmaculada Casas-Flecha; Cristina Avendaño-Solá; Rafael Duarte Palomino; Antonio Ramos-Martínez; Belén Ruiz-Antorán

    doi:10.21203/rs.3.rs-50154/v1 Date: 2020-07-28 Source: ResearchSquare

    Background: COVID-19 is a respiratory disease MESHD caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but the severity of the condition prompted the use of several pharmacological and non-pharmacological interventions. It has long been hypothesized that the use of convalescent plasma SERO (CP) from infected MESHD patients who have developed an effective immune response is likely to be an option for the treatment of patients with a variety of severe acute respiratory infections MESHD ( SARI MESHD) of viral etiology. The aim of this study is to assess the efficacy and safety of convalescent plasma SERO in adult TRANS patients with severe COVID-19 pneumonia HP pneumonia MESHD. Methods/Design: The ConPlas-19 study is a multicenter, randomized, open-label controlled trial. The protocol has been prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. The study has been planned to include 278 adult TRANS patients hospitalized with severe COVID-19 infection not requiring mechanical ventilation (invasive or non-invasive). Subjects are randomly assigned in a 1:1 ratio (139 per treatment arm), stratified by center, to receive intravenously administered CP (single infusion) plus SOC or SOC alone, and are to be followed for 30 days. The primary endpoint of the study is the proportion of patients that progress to categories 5, 6 or 7 (on the 7-point ordinal scale proposed by the WHO) at day 15. Interim analyses for efficacy and/or futility will be conducted once 20%, 40%, and 60% of the planned sample size are enrolled and complete D15 assessment.Discussion: This clinical trial is designed to evaluate the efficacy and safety of passive immunotherapy with convalescent plasma SERO for the treatment of adult TRANS patients hospitalized with COVID-19. The results of this study are expected to contribute to establishing the potential place of CP MESHD in the therapeutics for a new viral disease. Trial registration: Trial registration at clinicaltrials.gov; Registration Number: NCT04345523; https://clinicaltrials.gov/ct2/show/NCT04345523; Registered on 30 March, 2020. First posted date: April 14, 2020.

    RT-PCR testing to detect a COVID-19 outbreak in Austria: rapid, accurate and early diagnosis in primary care (The REAP study)

    Authors: Werner Leber; Oliver Lammel; Monika Redlberger-Fritz; Maria Elisabeth Mustafa-Korninger; Karin Stiasny; Reingard Christina Glehr; Eva-Maria Hochstrasser; Christian Hoellinger; Andrea Siebenhofer; Chris Griffiths; Jasmina Panovska-Griffiths

    doi:10.1101/2020.07.13.20152439 Date: 2020-07-15 Source: medRxiv

    Background Delay in COVID-19 detection has led to a major pandemic. We report rapid early detection of SARS-CoV-2 by reverse transcriptase-polymerase chain reaction (RT-PCR), comparing it to the serostatus of convalescent infection MESHD, at an Austrian National Sentinel Surveillance Practice in an isolated ski-resort serving a population of 22,829 people. Methods Retrospective dataset of all 73 patients presenting with mild to moderate flu-like symptoms to a sentinel practice in the ski-resort of Schladming-Dachstein, Austria, between 24 February and 03 April, 2020. We split the outbreak in two halves, by dividing the period from the first to the last case by two, to characterise the following three cohorts of patients with confirmed infection TRANS: people with reactive RT-PCR presenting during the first half (early acute infection MESHD) vs. those presenting in the second half (late acute), and people with non-reactive RT-PCR (late convalescent). For each cohort we report the number of cases detected, the accuracy of RT-PCR and the duration of symptoms. We also report multivariate regression of 15 clinical symptoms as covariates, comparing all people with convalescent infection MESHD to those with acute infection MESHD. Findings All 73 patients had SARS-CoV-2 RT-PCR testing. 22 patients were diagnosed with COVID-19, comprising: 8 patients presenting early acute, and 7 presenting late acute and 7 late convalescent respectively; 44 patients tested SARS-COV-2 negative, and 7 were excluded. RT-PCR sensitivity SERO was high (100%) among acute presenters, but dropped to 50% in the second half of the outbreak; specificity was 100%. The mean duration of symptoms was 2 days (range 1-4) among early acute presenters, and 4.4 days (1-7) among late acute and 8 days (2-12) among late convalescent presenters respectively. Convalescent infection MESHD was only associated with loss of taste MESHD (ORs=6.02;p=0.047). Acute infection MESHD was associated with loss of taste MESHD (OR=571.72;p=0.029), nausea and vomiting HP nausea and vomiting MESHD vomiting MESHD (OR=370.11;p=0.018), breathlessness (OR=134.46;p=0.049), and myalgia HP myalgia MESHD (OR=121.82;p=0.032); but not loss of smell, fever HP fever MESHD or cough HP cough MESHD. Interpretation RT-PCR rapidly and reliably detects early COVID-19 among people presenting with viral illness MESHD and multiple symptoms in primary care, particularly during the early phase of an outbreak. RT-PCR testing in primary care should be prioritised for effective COVID-19 prevention and control.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.